The US Food and Drug Administration would be authorized to require companies developing new combinations of cancer drugs to conduct pediatric studies under an amendment to user fee reauthorization legislation adopted by the House Energy & Commerce Committee.
At its 18 May markup of the measure, the committee voted unanimously in favor of an amendment by Rep. G.K. Butterfield, D-NC, to include his bill, Give Kids a Chance Act, H.R. 5416, in the user fee legislation
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?